不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
NCCN 指南® 洞察：B 细胞淋巴瘤，版本 5.2021
英文原题：NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.
查看英文原题
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在过去十年中，对B细胞非霍奇金淋巴瘤分子发病机制的深入理解促进了新型靶向治疗的发展，例如B细胞受体通路中选择性激酶的小分子抑制剂、抗体-药物偶联物，以及靶向多种蛋白（如CD-19、EZH2和XPO-1介导的核输出）的小分子药物。抗CD19 CAR-T 细胞疗法最初获批用于复发/难治性（R/R）弥漫大B细胞淋巴瘤，现也已成为R/R滤泡性淋巴瘤和套细胞淋巴瘤的新型治疗选择。这些NCCN指南见解重点介绍了NCCN B细胞淋巴瘤指南中纳入的用于治疗R/R疾病的新型靶向治疗选择。
展开英文摘要原文
In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody-drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1-mediated nuclear export).
Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.
论文信息
- 作者
- Zelenetz AD、Gordon LI、Chang JE、Christian B、Abramson JS、Advani RH、Bartlett NL、Budde LE
- 第一作者单位
- Memorial Sloan Kettering Cancer Center.
- 通讯作者单位
- National Comprehensive Cancer Network.
- 期刊
- Journal of the National Comprehensive Cancer Network : JNCCN2021 Nov
- 原文标识
- PubMed 34781267 · DOI 10.6004/jnccn.2021.0054